Peking University First Hospital
Tracked across 1 events · 6 articles · First seen Jul 20, 2026 · Last active Sep 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Alebund Pharmaceuticals announced that the U.S. United States — Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for AP308, a first-in-class engineered recombinant IgA protease for the treatment of IgA nephropathy…
Impact: Peking University First Hospital licensed the IgA protease technology to Alebund, contributing to the development of AP308.
Jul 20, 2026 · 6 articles
60
Alebund Pharmaceuticals entered license agreement Peking University First HospitalAlebund AP308 FDA IND Clearance
ERGEN INTELLIGENCE
Track Peking University First Hospital live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard